{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:50:01Z","timestamp":1786373401547,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.2215\/cjn.12371214","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T12:24:44Z","timestamp":1435926284000},"page":"1602-1608","source":"Crossref","is-referenced-by-count":65,"title":["The Safety of Eplerenone in Hemodialysis Patients"],"prefix":"10.2215","volume":"10","author":[{"given":"Michael","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Bueti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rabbat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Tyrwhitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Devereaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20230601","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1681\/ASN.V471486","article-title":"Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients.","volume":"4","author":"Harnett","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"R2-15-20230601","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2215\/CJN.07761109","article-title":"Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.","volume":"5","author":"Foley","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R3-15-20230601","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1525-139X.2003.160271.x","article-title":"Clinical epidemiology of cardiac disease in dialysis patients: Left ventricular hypertrophy, ischemic heart disease, and cardiac failure.","volume":"16","author":"Foley","year":"2003","journal-title":"Semin Dial"},{"key":"R4-15-20230601","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1681\/ASN.2007020220","article-title":"End-stage renal disease in the United States: An update from the United States Renal Data System.","volume":"18","author":"Foley","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R5-15-20230601","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis.","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"key":"R6-15-20230601","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/eurheartj\/15.suppl_D.45","article-title":"Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure.","volume":"15","author":"Brilla","year":"1994","journal-title":"Eur Heart J"},{"key":"R7-15-20230601","doi-asserted-by":"crossref","first-page":"12A","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.","volume":"71","author":"Brilla","year":"1993","journal-title":"Am J Cardiol"},{"key":"R8-15-20230601","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R9-15-20230601","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-15-20230601","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study.","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"R11-15-20230601","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R12-15-20230601","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2011.10.047","article-title":"Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.","volume":"59","author":"Frankenfield","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R13-15-20230601","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1136\/heart.85.4.e8","article-title":"Serious adverse events experienced by patients with chronic heart failure taking spironolactone.","volume":"85","author":"Berry","year":"2001","journal-title":"Heart"},{"key":"R14-15-20230601","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","article-title":"Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: The APOLLO trial.","volume":"35","author":"Teo","year":"2014","journal-title":"Eur Heart J"},{"key":"R15-15-20230601","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence: The importance of rigorous methods.","volume":"313","author":"Jones","year":"1996","journal-title":"BMJ"},{"key":"R16-15-20230601","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R17-15-20230601","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/ndt\/gfg413","article-title":"Is spironolactone safe for dialysis patients?","volume":"18","author":"Hussain","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R18-15-20230601","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients.","volume":"25","author":"Ito","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R19-15-20230601","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000210553","article-title":"Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.","volume":"114","author":"Matsumoto","year":"2009","journal-title":"Cardiology"},{"key":"R20-15-20230601","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R21-15-20230601","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic haemodialysis patients.","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R22-15-20230601","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function.","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R23-15-20230601","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R24-15-20230601","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5414\/CN106973","article-title":"Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients\u2014a pilot study.","volume":"76","author":"Shavit","year":"2011","journal-title":"Clin Nephrol"},{"key":"R25-15-20230601","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial.","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R26-15-20230601","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","article-title":"Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.","volume":"112","author":"Knoll","year":"2002","journal-title":"Am J Med"},{"key":"R27-15-20230601","first-page":"207","article-title":"Effect of haemodialysis on plasma ADH levels, plasma renin activity and plasma aldosterone levels in patients with end-stage renal disease.","volume":"110","author":"Iitake","year":"1985","journal-title":"Acta Endocrinol (Copenh"},{"key":"R28-15-20230601","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1291\/hypres.29.597","article-title":"Plasma aldosterone in hypertensive patients on chronic hemodialysis: Distribution, determinants and impact on survival.","volume":"29","author":"Kohagura","year":"2006","journal-title":"Hypertens Res"},{"key":"R29-15-20230601","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.HYP.0000124251.06056.8e","article-title":"Relations of serum aldosterone to cardiac structure: Gender-related differences in the Framingham Heart Study.","volume":"43","author":"Vasan","year":"2004","journal-title":"Hypertension"},{"key":"R30-15-20230601","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1053\/ajkd.2002.33407","article-title":"Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients.","volume":"39","author":"Yasuda","year":"2002","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201509000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:33Z","timestamp":1786369533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201509000-00015"}},"subtitle":["A Noninferiority Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12371214","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}